Ono Pharmaceutical Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 12 analysts
Updated 2026/08/01Earnings Calendar
Updated 2026/08/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/07/30 | ¥35.66 | ¥51.40 | +44.2% |
| 2026/05/07 | ¥15.64 | ¥1.74 | -88.9% |
| 2026/02/01 | ¥48.74 | ¥61.42 | +26.0% |
| 2025/10/29 | ¥46.54 | ¥47.71 | +2.5% |
Shareholder Composition
Updated 2026/08/01Top Mutual Funds / ETFs
Updated 2026/08/01Major Holders
Updated 2026/08/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
5.7M | -0.24% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
3.8M | +2.62% | |
|
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
|
3.7M | +79.68% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
2.7M | +1.24% | |
|
BlackRock Funds-BlackRock Advantage International Fund
|
1.9M | +20.78% | |
|
Dimensional ETF Trust-Dimensional International Value ETF
|
1.6M | +8.34% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
215.6K | +4.09% |
Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥40 | -50.0% |
| 2025 | ¥80 | 0.0% |
| 2024 | ¥80 | +3.9% |
| 2023 | ¥77 | +26.2% |
| 2022 | ¥61 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥361,361M | ¥447,187M | ¥502,672M | ¥486,871M |
| Gross Profit | ¥267,850M | ¥337,124M | ¥375,547M | ¥338,921M |
| Operating Income | ¥103,196M | ¥141,963M | ¥159,936M | ¥59,748M |
| Pretax Income | ¥105,899M | ¥144,445M | ¥163,963M | ¥64,646M |
| Net Income | ¥80,519M | ¥112,723M | ¥127,977M | ¥50,047M |
| EPS | ¥162.16 | ¥230.79 | ¥266.57 | ¥106.41 |
| Operating Margin | 28.56% | 31.75% | 31.82% | 12.27% |
| Balance Sheet | ||||
| Total Assets | ¥739,203M | ¥882,437M | ¥913,668M | ¥1,064,046M |
| Total Equity | ¥655,906M | ¥741,869M | ¥792,961M | ¥782,451M |
| Total Liabilities | ¥83,297M | ¥140,568M | ¥120,707M | ¥281,595M |
| Cash | ¥69,112M | ¥96,135M | ¥166,141M | ¥204,567M |
| Interest-bearing Debt | ¥8,802M | ¥9,168M | ¥8,862M | ¥146,678M |
| Equity Ratio | 88.73% | 84.07% | 86.79% | 73.54% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.19 |
| Cash Flow | ||||
| Operating CF | ¥61,829M | ¥159,610M | ¥110,660M | ¥82,459M |
| Investing CF | ¥6,038M | -¥100,259M | ¥48,077M | -¥136,785M |
| Financing CF | -¥60,237M | -¥32,484M | -¥89,848M | ¥94,299M |
| Free CF | ¥49,552M | ¥145,113M | ¥89,831M | ¥74,469M |
| Efficiency | ||||
| ROE | 12.28% | 15.19% | 16.14% | 6.40% |
| ROA | 10.89% | 12.77% | 14.01% | 4.70% |
Latest IR Information
-
Q1 FY2027 Financial Summary (Consolidated)
Ono Pharmaceutical's Q1 FY2027 financial results show net sales of 116.2 billion yen (YoY +0.4%) and net income of 17,631 million yen (YoY +1.0%). Overseas sales are approximately 12.9 billion yen, domestic sales about 87.8 billion yen. Key products include...
Read more -
Notice on Payment Completion for Share Buyback as Part of Employee Stock-based Compensation and Performance-based Restricted Stock Compensation
Payment completion of treasury stock for employee stock-based compensation and performance-based restricted stock compensation. The number of disposed shares is approximate, allocated to internal directors. A separate document discloses payment date, share count, and price.
Read more -
[Ono Pharmaceutical] Share Buyback and Employee Stock Compensation System Introduction | June 2026
Ono Pharmaceutical plans to dispose of 20,900 shares and 179,000 shares of treasury stock on July 10, 2026, and allocate approximately 4.47 billion yen to shareholders and executives. The system aims for medium- to long-term corporate value enhancement and management...
Read more -
【Ono Pharmaceutical】Full-Year Financial Results for 2026｜Sales: ¥515.7 billion, Net Income: ¥69.9 billion
Ono Pharmaceutical's consolidated sales for the fiscal year ending March 2026 are ¥515.7 billion (up 5.9% YoY), with net income of ¥69.9 billion (up 39.4% YoY), achieving revenue and profit growth. The forecast for 2027 predicts sales of ¥455.0 billion...
Read more -
Unknown
Ono Pharmaceutical Co., Ltd.'s consolidated financial results for 2025 (fiscal year ending March 2026) show sales of 486.9 billion yen (up 5.9% YoY), core operating profit of 112.7 billion yen (up 21.7% YoY), and net income attributable to owners of...
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥2,500
Rating Score: 2.83 (Based on 12 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; and Congruence Therapeutics. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
